间变性淋巴瘤激酶阳性大B细胞淋巴瘤的研究进展
Journal of Clinical Internal Medicine(2021)
Abstract
间变性淋巴瘤激酶(ALK)阳性的大B细胞淋巴瘤(ALK+LBCL)是一种罕见且具有高度侵袭性的非霍奇金淋巴瘤亚型,患者确诊时多处于晚期,对CHOP样方案联合放疗及造血干细胞移植(HSCT)反应较差、预后不良.ALK抑制剂克唑替尼(crizotinib)、ALK嵌合抗原受体T(CAR-T)细胞治疗、ALK抗体及B细胞淋巴瘤-2(Bcl-2)抑制剂的应用等治疗策略可能可以改善对CHOP样方案耐药的ALK+LBCL患者的预后.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined